Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01225562 · ClinicalTrials.gov registry record · Phase 3
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 21,379
- Enrollment target
NCT01225562 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 21,379 participants.
The verdict
NCT01225562, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 21,379 participants
- Enrollment target
Study Summary
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
Interventions
- DRUG Ticagrelor 90 mg
- DRUG Ticagrelor 60 mg
- DRUG Ticagrelor Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21,379 participants |
| Start Date | 2010-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01225562
The ClinicalTrials.gov registry entry for NCT01225562 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 21,379 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ticagrelor 90 mg is the first listed.
NCT01225562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01225562 about?
NCT01225562 is a clinical study titled "Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin". This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
What is the current status of trial NCT01225562?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 21,379 participants. The study started on 2010-10. Estimated completion is 2014-12.
What interventions are being tested in trial NCT01225562?
The interventions under investigation include: Ticagrelor 90 mg (DRUG), Ticagrelor 60 mg (DRUG), Ticagrelor Placebo (DRUG).
Who is sponsoring clinical trial NCT01225562?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.